



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re ~~Applicant~~ Applicant:

Michal AYALON-SOFFER et al.

Serial No.: 10/764,833

Filed: January 27, 2004

For: NOVEL POLYNUCLEOTIDES ENCODING
SOLUBLE POLYPEPTIDES AND METHODS
USING SAME

Examiner: WHALEY, Pablo S

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Group Art Unit: 1631
Attorney
Docket: 27256

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement is being filed subsequent to an Office Action being mailed and a late fee of \$180 is due. Please charge my Deposit Account 50-1407 for this fee, as well as any additional fees due.

This application claims the benefit of priority from U.S. Provisional Patent Application Nos. 60/322,285, filed September 14, 2001; 60/322,359, filed September 14, 2001; 60/322,506, filed September 14, 2001; 60/324,524, filed September 26, 2001; 60/354,242, filed February 6, 2002; 60/371,494, filed April 11, 2002; 60/384,096, filed May 31, 2002; 60/397,784, filed July 24, 2002; and from U.S. Patent Application Nos. 10/242,799, filed September 13, 2002; and 10/426,002, filed April 30, 2003.

01/11/2007 JADDO1 00000001 501407 10764833
01 FC:1806 180.00 DA


This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,



Martin D. Moynihan
Registration No. 40,338

Dated: January 3, 2007



PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

Approved for use through 07/31/2006. GMD 0031-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

11. *What is the primary purpose of the following statement?*

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
	7	WO 03/020953	03-13-2003	Sun et al.	
	8	WO 2005/071059	04-4-2005	Sorek et al.	
	9	WO 2005/068618	07-28-2005	Sella-Tavor et al.	
	10	WO 2005/071058	04-4-2005	Diber et al.	
	11	WO 2005/113596	01-1-2005	Jin et al.	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Complete if Known	
Application Number	10/764,833
Filing Date	January 27, 2004
First Named Inventor	Michal AYALON-SOFFER et al
Group Art Unit	1631
Examiner Name	WHALEY, Pablo S

Sheet	2	Of	3	Attorney Docket Number	27256
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	12	Benson et al. "GenBank", Nucleic Acids Research, 25(1): 1-6, 1997. P.1-5.			
	13	??? "AGENCOURT_6578352 NIH_MGC_41 Homo Sapiens cDNA Clone IMAGE: 5467535 5', mRNA Sequence", Database EMBL 'Online!', Database Accession No. BM556795, 2002.			
	14	NCBI The NCBI News, P.1-18, 1996.			
	15	Schr?der et al. "Isolation of A cDNA Encoding the Human GM2 Activator Protein", FEBS Letters, 251(1,2): 197-200, 1989.			
	16	Benson et al. "GenBank. Nucleic Acids Research, 25(1): 1-6, 1997. P.1-5.			
	17	Buetow et al. "High-Throughput Development and Characterization of A Genomewide Collection of Gene-Based Single Nucleotide Polymorphism Markers by Chip-Based Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry", Proc. Natl. Acad. Sci. US, 98(2): 581-584, 2001. Esp. P.581-583 A.			
	18	Loging et al. "Identifying Potential Tumor Markers and Antigens by Database Mining and Rapid Expression Screening", Genome Research, 10: 1393-1402, 2000. Esp. P.1393-1395.			
	19	Park et al. "Homo Sapiens mRNA for Met Proto-Oncogene", Database GenBank (GenEmbl), Accession No: X54559, 1999. Having 96.1% Sequence Identity With SEQ ID No: 3. Sequence Alignment.			
	20	Calabretta et al. "Antisense Oligonucleotides Targeting Cooperating Oncogenes", Database GenBank (GenEmbl), Accession No: I96185, 1998. Having 94% Sequence Identity With SEQ ID No: 3. Sequence Alignment.			
	21	Ma et al. "A Selective Small Molecule C-Met Inhibitor, PHA665752, Cooperates With Rapamycin", Clinical Cancer Research, 11: 2312-2319, 2005.			
	22	Abounader et al. "In Vivo Targeting of SF/HGF and C-Met Expression Via U1snRNA/Ribozymes Inhibits Glioma Growth and Angiogenesis and Promotes Apoptosis", The FASEB Journal, 16: 108-110, 2001.			
	23	Birchmeier et al. "Met, Metastasis, Motility and More", Nature Reviews: Molecular Cell Biology, 4: 915-925, 2003.			
	24	Brockmann et al. "Inhibition of Intracerebral Glioblastoma Growth by Local Treatment With the Scatter Factor/Hepatocyte Growth Factor-Antagonist NK4", Clinical Cancer Research, 9: 4578-4585, 2003.			
	25	Burgess et al. "Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor With Therapeutic Potential Against Hepatocyte Growth Factor/C-Met-Dependent Human Tumors", Cancer Research, 66(3): 1721-1729, 2006.			
	26	Hazkani-Covo et al. "Evolution of Multicellularity in Metazoa: Comparative Analysis of the Subcellular Localization of Proteins in Saccharomyces, Drosophila and Caenorhabditis", Cell Biology International, 28(3): 171-178, 2004.			

Signature	Considered
-----------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Complete if Known	
Application Number	10/764,833
Filing Date	January 27, 2004
First Named Inventor	Michal AYALON-SOFFER et al
Group Art Unit	1631
Examiner Name	WHALEY, Pablo S

Sheet	3	Of	3	Attorney Docket Number	27256
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	27	Christensen et al. "A Selective Small Molecule Inhibitor of C-Met Kinase Inhibits C-Met-Dependent Phenotypes In Vitro and Exhibits Cytoreductive Antitumor Activity In Vivo", Cancer Research, 63: 7345-7355, 2003.			
	28	Christensen et al. "C-Met as A Target for Human Cancer and Characterization of Inhibitors for Therapeutic Intervention", Cancer Letters, 225: 1-26, 2005.			
	29	Jagadeeswaran et al. "C-Met Receptor Tyrosine Kinase: A Novel Molecular Therapeutic Target for the Treatment of Pancreatic Cancer", Proceedings of the American Association of Cancer Research, 47: Abstract #3029, 2006. Abstract.			
	30	Kim et al. "Systemic Anti-Hepatocyte Growth Factor Monoclonal Antibody Therapy Induces the Regression of Intracranial Glioma Xenografts", Clinical Cancer Research, 12(4): 1292-1298, 2006.			
	31	Kong-Beltran et al. "The Sema Domain of Met Is Necessary for Receptor Dimerization and Activation", Cancer Cell, 6: 75-84, 2004.			
	32	Lal et al. "Targeting the C-Met Pathway Potentiates Glioblastoma Responses to Gamma-Radiation", Clinical Cancer Research, 11(12): 4479-4486, 2005.			
	33	Ma et al. "C-Met: Structure, Functions and Potential for Therapeutic Inhibition", Cancer and Metastasis Reviews, 22: 309-325, 2003.			
	34	Michieli et al. "Mutant Met-Mediated Transformation Is Ligand-Dependent and Can Be Inhibited by HGF Antagonists", Oncogene, 18: 5221-5231, 1999.			
	35	Michieli et al. "Targeting the Tumor and Its Microenvironment by Dual-Function Decoy Met Receptor", Cancer Cell, 6:61-73, 2004.			
	36	Saimura et al. "Intraperitoneal Injection of Adenovirus-Mediated NK4 Gene Suppresses Peritoneal Dissemination of Pancreatic Cancer Cell Line AsPC-1 in Nude Mice", Cancer Gene Therapy, 9: 799-806, 2002.			
	37	Tomioka et al. "Inhibition of Growth, Invasion, and Metastasis of Human Pancreatic Carcinoma Cells by NK4 in An Orthotopic Mouse Model", Cancer Research, 61: 7518-7524, 2001.			
	38	Webb et al. "The Gelanamycins Are Potent Inhibitors of the Hepatocyte Growth Factor/Scatter Factor-Met-Urokinase Plasminogen Activator-Plasmin Proteolytic Network", Cancer Research, 60: 342-349, 2000.			
	39	Wickramasinghe et al. "Met Activation and Receptor Dimerization in Cancer", Cell Cycle, 4(5): 683-685, 2005.			
	40	Zhang et al. "Met Decoys: Will Cancer Take the Bait?", Cancer Cell, 6: 5-6, 2004.			
	41	Bieche et al. "Overexpression of BRCA2 Gene in Sporadic Breast Tumours", Oncogene, 18: 5232-5238, 1999.			
	42	Knudsen et al. "The Retinoblastoma Tumor Suppressor Inhibits Cellular Proliferation Through Two Distinct Mechanisms: Inhibition of Cell Cycle Progression and Induction of Cell Death".			

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount